Home > Press > Particle Sciences sells T-COTE(R) Line of Microfine Titanium Dioxides to Sensient
Abstract:
Particle Sciences announced today that it has sold T-COTE, its proprietary line of microfine titanium dioxide, to Sensient. With the sale, Sensient assumes all marketing and sales responsibilities and acquires the associated trademarks and existing business. Particle Sciences will remain involved during the transition for technical support. The sale does not result in any change to the product, its specifications or method and location of manufacture.
Particle Science's has been a pioneer in nanotechnology. Its staff invented, among other things, Z-COTE, microfine zinc oxide, a product that was sold to BASF in 1999. These pigments are primarily used as sunscreens. Particle Sciences also developed several surface treatments for these and other particles. 'Particle Sciences has been at the cutting edge of fine particle technology for some time. We have a history of developing commercially successful products for ourselves and others,' said Garry Gwozdz, Director of Formulation Services at the company.
The sale is in keeping with Particle Sciences growth plan as it focuses on its pharmaceutical development services. According to Dr. Robert Lee, VP Pharmaceutical Development, 'Particle Sciences started, in 1991, as a topical formulation lab specializing in particulate API's. It has evolved into a leading provider of pharmaceutical development services ranging from preformulation to encapsulation to clinical trial material manufacturing. We remain expert in nano-delivery systems and provide a full suite of formulation and analytical services to our clients.'
####
About Particle Sciences
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
For more information, please click here
Contacts:
Maureen Cochran
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||